Endocrine Abstracts

Aims/objectives

The aims of the audit were to assess the monitoring of GLP-1 analogues if they were in accordance in monitoring to National institute of clinical excellence guidelines and appropriate in continuation and 6 months review with these guidelines.

Methods

A retrospective audit of 81 patients with Type 2 diabetes who were taking GLP-1 analogues between January 2010 and July 2019 at East Kent university hospitals was performed across both hospital sites in August 2019. The review time from initiation of the drugs varies between 10 years and 8 months. The data was collected from the hospital software systems and hard copy notes.

Results

The collected data demonstrated that 34.5%[28 patients] of patient’s continue to take the drugs despite that they were not meeting the criteria’s [reduction of at least 1% of HbA1c and 3% reduction of body Wight after 6 months] 51.% [[41 patients] of the patients met the criteria at assessment time but none reviewed in appropriate time, 13.58% [11 patients] never reviewed since initiation of treatment however only one patient stopped from taking these drugs.[because of side effects]. The audit demonstrates significant failure of our trust to be adherent to nice guidelines in monitoring of these drugs [reviewing after 6 months and continuation if reduction of at least 1% in HbA1c and 3% of body Wight reduction was achieved]. Conclusions: The audit demonstrated that standards for initiation were met but significant failure in reviewing and continuation criteria’s. We recommended GLP-1 mimetics monitoring form to be kept with patients of type2 DM notes and to be assessed by physician with each visit Were audit in July 2020 and the re audit data showed considerable improvement as 35% of the reviewed patient [28 patients] stopped from taking these drugs because they were not meeting the nice guidelines criteria’s for continuation.